IN8bio Inc Ordinary Shares INAB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
IN8bio Reports Third Quarter 2026 Financial Results and Recent Business Highlights
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
IN8bio to Present at Sidoti Small-Cap Virtual Conference
Sidoti Events, LLC's September Small-Cap Virtual Conference
IN8bio to Present at H.C. Wainwright 28th Annual Global Investment Conference
IN8bio Appoints Oxana Polyakova, Ph.D., as Senior Vice President of Research & Development
IN8bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $0.93
- Day Range
- $0.80–0.90
- 52-Week Range
- $0.80–2.73
- Bid/Ask
- $0.83 / $0.98
- Shares Outstanding
- 9.86M
- Market Cap
- $8.18M
- Volume/Avg
- 43,613 / 51,471
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cellular therapy product candidates and gamma-delta T cell engagers (TCEs) for cancer and autoimmune diseases. Gamma-delta T cells are a specialized population of T cells that possess properties. It has conducted two primary investigator-sponsored Phase 1 clinical trials evaluating its gamma-delta T cell technologies in cancer patients, which have both completed primary enrollment. INB-100 is assessing its DeltEx Allogeneic (Allo) gamma-delta T cell therapy in adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation (HSCT). It operates in a single segment.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 18
- Website
- https://www.in8bio.com
Valuation
Metric | INAB |
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.45 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
Metric | INAB |
|---|---|
Quick Ratio | 7.97 |
Current Ratio | 8.21 |
Interest Coverage | −283.90 |
Quick Ratio
INAB
Profitability
Metric | INAB |
|---|---|
Return on Assets (Normalized) | −70.90% |
Return on Equity (Normalized) | −84.99% |
Return on Invested Capital (Normalized) | −76.30% |
Return on Assets
INAB
Biotechnology Industry Comparables
1-Day Chart | Name | Price | Morningstar Rating for Stocks | Capital Allocation | Economic Moat | Market Cap |
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc VRTX | LOCK|yS!P^N | LOCK|T^?>y | $138B | |||
| Moderna Inc MRNA | LOCK|$Wxm@?< | LOCK|v$ | $96B | |||
| Regeneron Pharmaceuticals Inc REGN | LOCK|&br^Zp | LOCK|Kwn!r | $93B | |||
| argenx SE ADR ARGX | LOCK|?Q&lD> | LOCK|%X | $58B | |||
| BeOne Medicines Ltd ADR ONC | LOCK|FM!TXh | LOCK|d&> | $48B | |||
| Royalty Pharma PLC Class A RPRX | LOCK|!@PCg%%K | LOCK|?@kg | $30B | |||
| Incyte Corp INCY | LOCK|CCNXPw | LOCK|!d | $24B | |||
| BioNTech SE ADR BNTX | LOCK|%Nhlj@ | LOCK|#P | $21B | |||
| Alnylam Pharmaceuticals Inc ALNY | LOCK|nvCyd> | LOCK|Z^vV | $21B | |||
| Jazz Pharmaceuticals PLC JAZZ | LOCK|xLM#>T$ | LOCK|X$m | $15B |
United States